501 related articles for article (PubMed ID: 30872102)
21. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients.
Aubron C; Corallo CE; Nunn MO; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Oct; 45(10):1193-8. PubMed ID: 21896920
[TBL] [Abstract][Full Text] [Related]
22. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates.
Tasa T; Metsvaht T; Kalamees R; Vilo J; Lutsar I
Ther Drug Monit; 2017 Dec; 39(6):604-613. PubMed ID: 29084032
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.
Colin PJ; Allegaert K; Thomson AH; Touw DJ; Dolton M; de Hoog M; Roberts JA; Adane ED; Yamamoto M; Santos-Buelga D; Martín-Suarez A; Simon N; Taccone FS; Lo YL; Barcia E; Struys MMRF; Eleveld DJ
Clin Pharmacokinet; 2019 Jun; 58(6):767-780. PubMed ID: 30656565
[TBL] [Abstract][Full Text] [Related]
24. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
[TBL] [Abstract][Full Text] [Related]
25. External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients.
Wei S; Chen J; Zhao Z; Mei S
Eur J Clin Pharmacol; 2023 Aug; 79(8):1031-1042. PubMed ID: 37261482
[TBL] [Abstract][Full Text] [Related]
26. Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients.
Kallee S; Scharf C; Schatz LM; Paal M; Vogeser M; Irlbeck M; Zander J; Zoller M; Liebchen U
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145667
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin monitoring: one or two serum levels?
Andrés I; López R; Pou L; Piñol F; Pascual C
Ther Drug Monit; 1997 Dec; 19(6):614-9. PubMed ID: 9421100
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model-informed precision dosing trial simulations.
Aljutayli A; Thirion DJG; Bonnefois G; Nekka F
Clin Transl Sci; 2022 Apr; 15(4):942-953. PubMed ID: 35170243
[TBL] [Abstract][Full Text] [Related]
29. Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.
Carreno JJ; Lomaestro B; Tietjan J; Lodise TP
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289024
[TBL] [Abstract][Full Text] [Related]
30. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
Fewel N
J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
[TBL] [Abstract][Full Text] [Related]
32. Validation of a pediatric population pharmacokinetic model for vancomycin.
Hahn A; Frenck RW; Zou Y; Vinks AA
Ther Drug Monit; 2015 Jun; 37(3):413-6. PubMed ID: 25423413
[TBL] [Abstract][Full Text] [Related]
33. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin.
Salehpour N; Riley LD; Gonzales MJ; Kobic E; Nix DE
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017223. PubMed ID: 37133362
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
Zhao W; Zhang D; Fakhoury M; Fahd M; Duquesne F; Storme T; Baruchel A; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2014 Jun; 58(6):3191-9. PubMed ID: 24663023
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
Haeseker M; Croes S; Neef C; Bruggeman C; Stolk L; Verbon A
Ther Drug Monit; 2016 Feb; 38(1):120-6. PubMed ID: 26418699
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis.
Stocker SL; Carland JE; Reuter SE; Stacy AE; Schaffer AL; Stefani M; Lau C; Kirubakaran R; Yang JJ; Shen CFJ; Roberts DM; Marriott DJE; Day RO; Brett J
Clin Pharmacol Ther; 2021 Jan; 109(1):212-221. PubMed ID: 33190285
[TBL] [Abstract][Full Text] [Related]
38. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
[TBL] [Abstract][Full Text] [Related]
39. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
40. Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.
Greppmair S; Brinkmann A; Roehr A; Frey O; Hagel S; Dorn C; Marsot A; El-Haffaf I; Zoller M; Saller T; Zander J; Schatz LM; Scharf C; Briegel J; Minichmayr IK; Wicha SG; Liebchen U
Intensive Care Med; 2023 Aug; 49(8):966-976. PubMed ID: 37439872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
